文献速递产科母胎医学

接受低剂量阿司匹林治疗的高危孕妇中肥胖与实验室阿司匹林抵抗的关系

Obesity and laboratory aspirin resistance in high-risk pregnant women treated with low-dose aspirin.
PubMed 文献 · Am J Obstet Gynecol · 2019-02-17

本研究为一项前瞻性多中心研究的二次分析,纳入1002例高危孕妇,其中低剂量阿司匹林组496例(49.5%)、安慰剂组506例(50.5%),探讨肥胖与血小板源性血栓素抑制的关联。结果显示,在低剂量阿司匹林组中,III级肥胖女性在孕中期和孕晚期完全抑制TXB2的几率最低。作者认为,该人群可能需要增加阿司匹林剂量或给药频率。

要点

  • 低剂量阿司匹林组各BMI类别TXB2水平均大幅下降。
  • III级肥胖女性孕中期完全抑制TXB2的aOR为0.33(95%CI 0.15-0.72)。
  • 作者认为肥胖高危孕妇可能需要增加阿司匹林剂量或频率。

核心结论

  • 接受低剂量阿司匹林预防子痫前期的高危肥胖女性完全抑制TXB2的比例较低,作者认为该人群可能需要增加阿司匹林剂量或给药频率。

研究设计与样本

  • 本研究为一项探讨低剂量阿司匹林(60 mg)在高危孕妇中作用的前瞻性多中心研究的二次分析,共纳入1002例患者,低剂量阿司匹林组496例(49.5%)、安慰剂组506例(50.5%)。

主要发现

  • 低剂量阿司匹林组各BMI类别TXB2水平均大幅下降,而安慰剂组随机化后TXB2水平无明显下降。
  • 在安慰剂组中,肥胖女性孕中期TXB2中位水平为16.5 ng/mL(IQR 8.0-31.8) vs 非肥胖女性14.0 ng/mL(IQR 6.9-26.7),P=.032;孕晚期为15.7 ng/mL(IQR 7.6-28.5) vs 11.9 ng/mL(IQR 4.6-25.9),P=.043。
  • 在低剂量阿司匹林组各BMI类别中,III级肥胖女性孕中期完全检测不到TXB2水平的aOR为0.33(95%CI 0.15-0.72),孕晚期aOR为0.30(95%CI 0.11-0.78),两个时间点aOR为0.09(95%CI 0.02-0.41)。

关键数值与推荐

  • 完全TXB2抑制定义为TXB2<0.01 ng/mL。
  • 多变量logistic回归分析调整了母亲年龄、种族、随机化时高危分组、未产及随机化时孕周小于16周的比例。

临床怎么用

  • 作者认为,对于接受低剂量阿司匹林预防子痫前期的高危肥胖女性,可能需要增加阿司匹林剂量或给药频率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low-dose aspirin is used for preeclampsia prevention in high-risk women, but the precise mechanism and optimal dose are unknown. Evidence suggests that an imbalance in prostacyclin and thromboxane A2 (TXA2) plays a key role in the pathogenesis of preeclampsia. Aspirin has a dose-dependent effect blocking production of TXA2, a potent stimulator of platelet aggregation and promoter of vasoconstriction. Incomplete inhibition of platelet aggregation, designated aspirin resistance, can be reduced by increasing the aspirin dose. Evidence in the nonobstetric literature suggests that aspirin resistance may be more common among patients with a high body mass index. OBJECTIVE: To investigate the association of obesity on platelet-derived thromboxane inhibition in high-risk women treated with low-dose aspirin. MATERIALS AND METHODS: This was a secondary analysis of a prospective multi-centered study investigating the effect of low-dose aspirin (60-mg) administration in women at high risk for preeclampsia. Maternal serum TXB2 (an indirect measure of TxA2) levels were drawn at 3 time points: randomization (13-26 weeks' gestation), second trimester (at least 2 weeks after randomization and 24-28 weeks' gestation), and third trimester (34-38 weeks' gestation). Patients were included in the analysis if a TXB2 level was recorded at randomization and at least 1 time point thereafter. Patients were stratified by body mass index category and treatment arm. Median TXB2 levels were calculated at each time point, as well as rates of complete TXB2 inhibition (<0.01 ng/mL). A multivariate logistic regression analysis was performed to generate odds ratios (OR) for complete TXB2 inhibition by body mass index category, adjusting for maternal age, race, high-risk group at randomization, nulliparity, and rate of randomization less than 16 weeks' gestation. RESULTS: A total of 1002 patients were included in the analysis, 496 (49.5%) and 506 (50.5%) in the low-dose aspirin and placebo groups respectively. There were substantial decreases in TXB2 levels among low-dose aspirin-treated women in all body mass index categories. In contrast, women assigned to placebo did not show a marked decrease in TXB2 levels after randomization, and obese women had higher median TXB2 levels in both the second (16.5, interquartile range [IQR] 8.0-31.8 vs 14.0, IQR 6.9-26.7, ng/mL; P = .032) and third (15.7, IQR 7.6-28.5 vs 11.9, IQR 4.6-25.9, ng/mL; P = .043) trimesters. When comparing among stratified body mass index low-dose aspirin groups, women with class III obesity had the lowest odds of undetectable TXB2 levels in the second trimester (adjusted odds ratio [aOR], 0.33; 95% confidence interval [CI], 0.15-0.72) and third trimester (aOR, 0.30; 95% CI, 0.11-0.78) as well as at both time points (aOR, 0.09; 95% CI, 0.02-0.41). CONCLUSION: High-risk obese women receiving low-dose aspirin for the prevention of preeclampsia have lower rates of complete inhibition of TXB2. These data suggest that an increase in aspirin dosing or frequency may be necessary in this population.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Finneran MM, Gonzalez-Brown VM, Smith DD, et al. Obesity and laboratory aspirin resistance in high-risk pregnant women treated with low-dose aspirin. Am J Obstet Gynecol. 2019. PMID: 30786253. doi:10.1016/j.ajog.2019.01.222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。